Forecast

There is no analyst data available for this company.

News Go to news feed

H. Lundbeck posts strong H1 growth thanks to Vyepti, confirms full-year outlook

H. Lundbeck reported currency-adjusted revenue growth of 16% in H1 2026 to DKK 13.6bn, driven by Vyepti (+46% worldwide, US market share 13.01%) and REXULTI (+17%). Adjusted EBITDA rose 19% and adjusted EPS increased 28%; net debt fell to DKK 7.4bn. Management did not raise the outlook but sees the company at the upper end of the full-year guidance (revenue +7–9%, EBITDA +8–14%) and warns of a normalization of effects in H2. Lundbeck continues to emphasize high R&D investment and several upcoming study readouts as future catalysts. » More on de.investing.com
Lundbeck share plunges after slowed adjusted growth and exchange offer

The Lundbeck share fell 6.7% today to 41.81 after half-year figures showed total sales growth of +16% CER but a slowed adjusted growth of +13% CER versus +21% in Q1. Additional pressure came from a voluntary 1:1 exchange offer by majority shareholder Lundbeckfond Invest A/S, which increases the supply of B shares and could trigger selling. Neutral FTSE 100 trading, geopolitical tensions and technical sell signals amplified the negative price reaction. » More on de.investing.com
Lundbeck reports mixed Q4 results and gives outlook to 2026

Lundbeck reported Q4 revenue of DKK 6.09 billion and adjusted EBITDA of DKK 1.61 billion, beating expectations by 4%, while adjusted earnings per share of DKK 0.94 missed consensus. The company announced a dividend of DKK 1.15. For 2026 Lundbeck forecasts revenue growth of 5–8% at constant exchange rates (DKK 24.83–25.54 billion) and adjusted EBITDA growth of 4–12% (DKK 7.46–8.03 billion), but sees negative currency effects and higher R&D spending. Lundbeck warns of increasing generic pressure on Abilify and a pipeline that is unlikely to deliver revenues before 2028, creating mid‑term revenue risks. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2002, H. Lundbeck has already paid €1.30 in dividends. The last payout was in April 2002.

Financials

In the last quarter, H. Lundbeck had revenue of €872.16M and net profit of €153.59M

(EUR)	Jun 2026	YoY
Revenue	872.16M	8.03%
Gross profit	689M	4.23%
Net profit	153.59M	18.62%
EBITDA	271.19M	28.79%

Fundamentals

Metric	Value
Market capitalization	€0
52-week high/low	€23.40 - €22.85
Dividends	No
Beta	0.61
P/E ratio	10.59
PEG ratio	0.93
P/B ratio	1.53
P/S ratio	1.28

Company profile

H. Lundbeck A/S, ein biopharmazeutisches Unternehmen, erforscht, entwickelt, produziert und vertreibt Arzneimittel für die Behandlung von psychiatrischen und neurologischen Erkrankungen in Europa, Nordamerika und international. Zu den wichtigsten Produkten des Unternehmens gehören Abilify Maintena zur Behandlung von Schizophrenie, Brintellix/Trintellix zur Behandlung von Depressionen, Northera zur Behandlung der symptomatischen neurogenen orthostatischen Hypotonie, Vyepti zur Migräneprävention und Rexulti/Rxulti zur Behandlung von Depressionen/Schizophrenie. Darüber hinaus bietet es Azilect zur Behandlung der Parkinson-Krankheit, Cipralex/Lexapro zur Behandlung von Depressionen, Ebixa zur Behandlung der Alzheimer-Krankheit, Onfi zur Behandlung des Lennox-Gastaut-Syndroms, Sabril zur Behandlung von Epilepsie und Xenazine zur Behandlung von Chorea im Zusammenhang mit der Huntington-Krankheit sowie weitere Produkte an. Das Unternehmen verkauft seine Produkte hauptsächlich an Pharmahändler, Apotheken und Krankenhäuser. Es hat eine Partnerschaftsvereinbarung mit Verantos geschlossen, um sich auf eine Studie zur Unterstützung der Migränetherapie zu konzentrieren, und arbeitet mit Rgenta Therapeutics, Inc. Das Unternehmen wurde 1915 gegründet und hat seinen Hauptsitz in Valby, Dänemark.